Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
This week, the FDA is expected to release its approval decision for the non-opioid painkiller made by Vertex Pharmaceuticals Inc. The company that can capture the pain medicine market could hit a ...
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback